Monitoring, management, and outcome of hypotension in Intensive Care Unit patients, an international survey of the European Society of Intensive Care Medicine.

Introduction: Hypotension in the ICU is common, yet management is challenging and variable. Insight in management by ICU physicians and nurses may improve patient care and guide future hypotension treatment trials and guidelines.
Methods: We conducted an international survey among ICU personnel to provide insight in monitoring, management, and perceived consequences of hypotension.
Results: Out of 1464 respondents, 1197 (81.7%) were included (928 physicians (77.5%) and 269 nurses (22.5%)). The majority indicated that hypotension is underdiagnosed (55.4%) and largely preventable (58.8%). Nurses are primarily in charge of monitoring changes in blood pressure, physicians are in charge of hypotension treatment. Balanced crystalloids, dobutamine, norepinephrine, and Trendelenburg position were the most frequently reported fluid, inotrope, vasopressor, and positional maneuver used to treat hypotension. Reported complications believed to be related to hypotension were AKI and myocardial injury. Most ICUs do not have a specific hypotension treatment guideline or protocol (70.6%), but the majority would like to have one in the future (58.1%).
Conclusions: Both physicians and nurses report that hypotension in ICU patients is underdiagnosed, preventable, and believe that hypotension influences morbidity. Hypotension management is generally not protocolized, but the majority of respondents would like to have a specific hypotension management protocol.
Competing Interests: Declaration of Competing Interest TWLS received research grants and honoraria from Edwards Lifesciences (Irvine, CA, USA) and Masimo Inc. (Irvine, CA, USA) for consulting and lecturing and from Pulsion Medical Systems SE (Feldkirchen, Germany) for lecturing (all payments made to institution). DPV reported receipt of personal fees and other from Edwards Lifesciences (Irvine, CA, USA) as well as consultancy fees and research grants from Philips (Eindhoven, the Netherlands) and Hemologic (Amersfoort, the Netherlands). APJV reported receipt of grants from Edwards Lifesciences (Irvine, CA, USA) and Philips (Eindhoven, the Netherlands). WHV, JS, JS, SR, TGVC, WKL, PT, PWGE, PRT, JB, BFG, and FP declare that they have no conflicts of interest.
(Copyright © 2021 The Author(s). Published by Elsevier Inc. All rights reserved.)